Published: 2019 April 09
Updated : 2022 June 13

Systemic Sclerosis Market Size, Competitive Landscape and Market Forecast - 2029

SKU : PH32
180 pages
Report Summary
Table of Contents

Global Systemic Sclerosis Market is segmented By Type (Limited, Diffuse), By Drug Type (Corticosteroids, Immunosuppressive Agents, Endothelin Receptor Agonists, Calcium Channel Blockers, Phosphodiesterase 5 Inhibitors, Chelating Agents, Prostacyclin Analogues, H2 Blockers, Proton Pump Inhibitors, ACE Inhibitors), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029


Market Overview

The Global Systemic Sclerosis Market is expected to grow at a CAGR of 6.0% during the forecasting period (2022-2029).

  • Systemic sclerosis (SSc) is a systemic connective tissue disease of unknown etiology that affects the skin, blood vessels, muscles, joints, and a variety of internal organs, such as the digestive tract, heart, lungs, and kidneys.

  • The global Systemic sclerosis treatment market is estimated to reach USD 1.4 million by 2024.

Market Growth

  • Primary market drivers include increased use of expensive biologics, the rise in clinical trials for systemic sclerosis, high acceptance of new therapies by patients, and new drug approvals.

  • However, delay in diagnosis and lack of safe and effective treatments will restrain the market growth.

Market Segmentation

  • The Global Systemic sclerosis market report segments the market by type, drug type, and region.

  • Based on the extent of skin involvement, the market is segmented into Limited cutaneous systemic sclerosis (lcSSc), or limited scleroderma, and Diffuse cutaneous systemic sclerosis (dcSSc), or diffuse scleroderma.

  • Limited cutaneous systemic sclerosis is the more common type of SSc.

  • Based on drug type, the market is segmented into Corticosteroids, Immunosuppressive Agents, Endothelin Receptor Agonists, Calcium Channel Blockers, PDE-5 Inhibitors, Chelating Agents, Prostacyclin Analogues, H2 Blockers, Proton Pump Inhibitors, and ACE Inhibitors.

  • Regarding the drug category, the segment of immunosuppressive agents is expected to retain dominance over the forecast period.

  • Regionally, the market is segmented into five major regions, namely North America, South America, Europe, Asia Pacific, and RoW.

  • North America will dominate the market. The US has an annual incidence of about 20 cases per 1 million adults.

Scope of the Report

  • The report profiles the following companies of Systemic sclerosis market – Actelion, Roche/Genentech, BMS, Allergan, GSK, Biogen, Novartis, Teva, MedImmune, Celgene, Chugai, ASTA, Aspen, Pfizer, Eli Lilly, Bayer, and many more.

By Type

  • Limited

  • Diffuse

By Drug Type

  • Corticosteroids

  • Immunosuppressive Agents

  • Endothelin Receptor Agonists

  • Calcium Channel Blockers

  • Phosphodiesterase 5 Inhibitors

  • Chelating Agents

  • Prostacyclin Analogues

  • H2 Blockers

  • Proton Pump Inhibitors

  • ACE Inhibitors

By Region

  • Asia Pacific (China, Japan, India, Australia, Rest of Asia Pacific)

  • Europe (Germany, France, The UK, Italy, Spain, Rest of Europe)

  • North America (The USA, Canada, Mexico)

  • South America (Brazil, Argentina, Rest of South America)

  • Rest of the World

Trending Topics

Astragalus Polysaccharide Market

Immunosuppressants Drugs Market

Remote Patient Monitoring Market

Buy this report
Single User
Multiple User
Enterprise User
Proceed to Buy